Overview
Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
Status:
Completed
Completed
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the safety, efficacy, and activity of patupilone in patients with advanced unresectable and/or metastatic hepatocellular carcinoma based on tumor response using modified RECIST criteria.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis PharmaceuticalsTreatments:
Epothilone B
Epothilones
Criteria
Inclusion criteria:- Hepatocellular carcinoma patients with at least 1 previously un-irradiated, measurable
lesion without any systemic single agent or combination chemotherapy. Previous local
therapy is allowed.
Exclusion criteria:
Additional protocol-defined inclusion/exclusion criteria apply.